Zacks.com on MSN12h
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer TherapyMRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell ...
Pharmaceutical Technology on MSN22h
MSD secures worldwide license for LaNova’s LM-299MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...
Zacks.com on MSN13h
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline SetbackThe third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback